Submit to Special Issue Submit Abstract to Special Issue Review for Pharmaceuticals Propose a Special Issue

Journal Menu

Journal Browser

Special Issue "New Trends in Applications and Production of Metal Radionuclides for Nuclear Medicine"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Published Papers

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: 20 October 2023 | Viewed by 2717

Share This Special Issue

Special Issue Editors

Dr. Gaia Pupillo

E-Mail Website
Guest Editor

National Institute for Nuclear Physics, Legnaro National Laboratories, Viale dell’Università 2, 35020 Legnaro, Padua, Italy
Interests: radionuclide production; nuclear cross section measurements; gamma spectroscopy; charged-particles-induced reactions; theranostic radionuclides; cyclotron production

Dr. Petra Martini

E-Mail Website
Guest Editor

Department of Environmental and Prevention Sciences (DEPS), University of Ferrara Via Luigi Borsari, 46 44121 Ferrara, Italy
Interests: radioisotope cyclotron production; radiometal separation; synthesis module automation; radiopharmaceuticals; radiochemistry; nuclear medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of radiopharmaceuticals is constantly evolving thanks to the great contribution of specialists coming from different disciplines, such as inorganic chemistry, radiochemistry, organic and biochemistry, pharmacology, nuclear medicine, physics, material sciences, engineering, etc. In particular, the use of radiometals has experienced a great increase as a result of new developments of radionuclide production technologies.

A major trend in the field of nuclear medicine research is the use of radiometals for PET and SPECT (⁶⁸Ga, ⁶⁴Cu, ⁸⁹Zr, ⁴⁴Sc, ⁸⁶Y, ⁵²Mn, ^99mTc, etc.), for therapy (¹⁷⁷Lu, ⁹⁰Y ,⁸⁹Sr, ²²³Ra, ²²⁵Ac, etc.), and for theranostics (⁶⁷Cu, ⁴⁷Sc, ¹⁴⁹Tb, the theranostic pairs, etc.).

The production and application of conventional and newly emerging research radiometals are the main focus of this new Special Issue entitled “New Trends in Production and Applications of Metal Radionuclides for Nuclear Medicine”. You are cordially invited to contribute to this Issue with original research articles, reviews and short communications. Areas of interest include, but are not limited to, the following topics:

Innovative routes for medical radionuclides production: accelerators and nuclear reactors;
Innovative targets for emerging radiometals production: methods and technology;
Radiometals separation: methods and technology;
Radiopharmaceuticals synthesis automation: methods and technology;
Radiometals and radiopharmaceuticals chemistry;
Theranostics radiopharmaceuticals: production and applications;
Multimodality imaging radiopharmaceuticals: production and applications;
Innovative radio-probes for nuclear imaging and therapy;
Towards individualized dosimetry: preclinical studies with innovative radiopharmaceuticals.

Dr. Gaia Pupillo
Dr. Petra Martini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Radionuclide Cisternography with [⁶⁴Cu]Cu-DOTA

and

Pharmaceuticals 2023, 16(9), 1269; https://doi.org/10.3390/ph16091269 - 07 Sep 2023

Viewed by 246

Abstract

Radionuclide cisternography (RNC) is a method for conducting imaging of the cerebrospinal system and can be used to identify cerebrospinal fluid leaks. So far, RNC has commonly employed radiopharmaceutical agents suitable only for single-photon emission tomography techniques, which are thus lacking in terms of image resolution and can potentially lead to false-negative results. Therefore, [⁶⁴Cu]Cu-DOTA was investigated as an alternative radiopharmaceutical for RNC, employing positron emission tomography (PET) instead of single-photon emission tomography. A formulation of [⁶⁴Cu]Cu-DOTA was produced according to the guidelines for good manufacturing practice. The product met the requirements of agents suitable for intrathecal application. [⁶⁴Cu]Cu-DOTA was administered to a patient and compared to the approved scintigraphic RNC agent, [¹¹¹In]In-DTPA. While no cerebrospinal fluid leak was detected with [¹¹¹In]In-DTPA, [⁶⁴Cu]Cu-DOTA RNC exhibited a posterolateral leak between the vertebral bodies C1 and C2. Thus, in this patient, PET RNC with [⁶⁴Cu]Cu-DOTA was superior to RNC with [¹¹¹In]In-DTPA. Since radiopharmaceuticals have a very good safety profile regarding the occurrence of adverse events, PET RNC with [⁶⁴Cu]Cu-DOTA may become an attractive alternative to scintigraphic methods, and also to computed tomography or magnetic resonance imaging, which often require contrast agents, causing adverse events to occur much more frequently. Full article

(This article belongs to the Special Issue New Trends in Applications and Production of Metal Radionuclides for Nuclear Medicine)

► Show Figures

Figure 1

Open AccessArticle

Cyclotron-Based Production of ⁶⁷Cu for Radionuclide Theranostics via the ⁷⁰Zn(p,α)⁶⁷Cu Reaction

Santiago Andrés Brühlmann

and

Pharmaceuticals 2023, 16(2), 314; https://doi.org/10.3390/ph16020314 - 17 Feb 2023

Cited by 2 | Viewed by 1364

Abstract

Theranostic matched pairs of radionuclides have aroused interest during the last couple of years, and in that sense, copper is one element that has a lot to offer, and although ⁶¹Cu and ⁶⁴Cu are slowly being established as diagnostic radionuclides for PET, the availability of the therapeutic counterpart ⁶⁷Cu plays a key role for further radiopharmaceutical development in the future. Until now, the ⁶⁷Cu shortage has not been solved; however, different production routes are being explored. This project aims at the production of no-carrier-added ⁶⁷Cu with high radionuclidic purity with a medical 30MeV compact cyclotron via the ⁷⁰Zn(p,α)⁶⁷Cu reaction. With this purpose, proton irradiation of electrodeposited ⁷⁰Zn targets was performed followed by two-step radiochemical separation based on solid-phase extraction. Activities of up to 600MBq ⁶⁷Cu at end of bombardment, with radionuclidic purities over 99.5% and apparent molar activities of up to 80MBq/nmol, were quantified. Full article

(This article belongs to the Special Issue New Trends in Applications and Production of Metal Radionuclides for Nuclear Medicine)

► Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview

Lights and Shadows on the Sourcing of Silver Radioisotopes for Targeted Imaging and Therapy of Cancer: Production Routes and Separation Methods

Marianna Tosato

and

Mattia Asti

Pharmaceuticals 2023, 16(7), 929; https://doi.org/10.3390/ph16070929 - 26 Jun 2023

Viewed by 621

Abstract

The interest in silver radioisotopes of medical appeal (silver-103, silver-104m,g and silver-111) has been recently awakened by the versatile nature of their nuclear decays, which combine emissions potentially suitable for non-invasive imaging with emissions suited for cancer treatment. However, to trigger their in vivo application, the production of silver radioisotopes in adequate amounts, and with high radionuclidic purity and molar activity, is a key prerequisite. This review examines the different production routes of silver-111, silver-103 and silver-104m,g providing a comprehensive critical overview of the separation and purification strategies developed so far. Aspects of quality (radiochemical, chemical and radionuclidic purity) are also emphasized and compared with the aim of pushing towards the future implementation of this theranostic triplet in preclinical and clinical contexts. Full article

(This article belongs to the Special Issue New Trends in Applications and Production of Metal Radionuclides for Nuclear Medicine)

► Show Figures

Journal Menu

Journal Browser

Special Issue "New Trends in Applications and Production of Metal Radionuclides for Nuclear Medicine"

Share This Special Issue

Special Issue Editors

Special Issue Information

Published Papers (3 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI